Compare Ally Financial Inc (ALLY) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $43.85 (market cap $13.37B), while Amphastar Pharmaceuticals Inc trades at $19.91 (market cap $868.62M). The key difference: Ally Financial Inc is far larger — about 15.4× Amphastar Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | AMPH | |
|---|---|---|
Market Cap | $13.37B | $868.62M |
Sector | Financials | Health |
52-Week High | $47.25 | $30.81 |
52-Week Low | $35.96 | $16.87 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.81, showing minimal daily movement. The stock exhibits a bearish technical signal with recent earnings missing estimates in Q2 2026, though revenue grew 10% year-over-year. Valuation metrics appear attractive with a P/E of 10.34 and P/B below 1. Analyst consensus remains strongly bullish with a $54.40 price target, but insider selling and mixed technical indicators suggest near-term caution.
The outlook for ALLY hinges on execution amid macroeconomic pressures. Upside potential exists from solid loan growth and digital banking strength, but risks include rising provisions, competitive pressures, and interest rate sensitivity. Earnings growth in upcoming quarters is critical for sustaining investor confidence and driving the stock toward analyst targets.
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
